Literature DB >> 22644789

A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.

Laura E Gibbons1, Adam C Carle, R Scott Mackin, Danielle Harvey, Shubhabrata Mukherjee, Philip Insel, S McKay Curtis, Dan Mungas, Paul K Crane.   

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) measures abilities broadly related to executive function (EF), including WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing. This study investigates whether a composite executive function measure based on these multiple indicators has better psychometric characteristics than the widely used individual components. We applied item response theory methods to 800 ADNI participants to derive an EF composite score (ADNI-EF) from the above measures. We then compared ADNI-EF with component measures in 390 longitudinally-followed participants with mild cognitive impairment (MCI) with respect to: (1) Ability to detect change over time; (2) Ability to predict conversion to dementia; (3) Strength of cross-sectional association with MRI-derived measures of structures involved in frontal systems, and (4) Strength of baseline association with cerebrospinal fluid (CSF) levels of amyloid β₁₋₄₂, total tau, and phosphorylated tau(181P). ADNI-EF showed the greatest change over time, followed closely by Category Fluency. ADNI-EF needed a 40 % smaller sample size to detect change. ADNI-EF was the strongest predictor of AD conversion. ADNI-EF was the only measure significantly associated with all the MRI regions, though other measures were more strongly associated in a few of the regions. ADNI-EF was associated with all the CSF measures. ADNI-EF appears to be a useful composite measure of EF in MCI, as good as or better than any of its composite parts. This study demonstrates an approach to developing a psychometrically sophisticated composite score from commonly-used tests.

Entities:  

Mesh:

Year:  2012        PMID: 22644789      PMCID: PMC3684181          DOI: 10.1007/s11682-012-9176-1

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.978


  35 in total

Review 1.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Danielle Harvey; Charles DeCarli
Journal:  Arch Neurol       Date:  2009-09

3.  Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness.

Authors:  Yu-Ling Chang; Mark W Jacobson; Christine Fennema-Notestine; Donald J Hagler; Robin G Jennings; Anders M Dale; Linda K McEvoy
Journal:  Cereb Cortex       Date:  2009-09-23       Impact factor: 5.357

4.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

7.  Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR.

Authors:  Christopher Schwarz; Evan Fletcher; Charles DeCarli; Owen Carmichael
Journal:  Inf Process Med Imaging       Date:  2009

8.  Composite scores for executive function items: demographic heterogeneity and relationships with quantitative magnetic resonance imaging.

Authors:  Paul K Crane; Kaavya Narasimhalu; Laura E Gibbons; Otto Pedraza; Kala M Mehta; Yuxiao Tang; Jennifer J Manly; Bruce R Reed; Dan M Mungas
Journal:  J Int Neuropsychol Soc       Date:  2008-09       Impact factor: 2.892

9.  Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Authors:  R C Petersen; P S Aisen; L A Beckett; M C Donohue; A C Gamst; D J Harvey; C R Jack; W J Jagust; L M Shaw; A W Toga; J Q Trojanowski; M W Weiner
Journal:  Neurology       Date:  2009-12-30       Impact factor: 9.910

10.  The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Authors:  Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

View more
  180 in total

1.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

2.  Integrating molecular, histopathological, neuroimaging and clinical neuroscience data with NeuroPM-box.

Authors:  Yasser Iturria-Medina; Félix Carbonell; Atousa Assadi; Quadri Adewale; Ahmed F Khan; Tobias R Baumeister; Lazaro Sanchez-Rodriguez
Journal:  Commun Biol       Date:  2021-05-21

3.  Cognitive decline impairs financial and health literacy among community-based older persons without dementia.

Authors:  Patricia A Boyle; Lei Yu; Robert S Wilson; Eisuke Segawa; Aron S Buchman; David A Bennett
Journal:  Psychol Aging       Date:  2013-08-19

4.  Genetic modification of the relationship between phosphorylated tau and neurodegeneration.

Authors:  Timothy J Hohman; Mary Ellen I Koran; Tricia A Thornton-Wells
Journal:  Alzheimers Dement       Date:  2014-03-20       Impact factor: 21.566

5.  Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort.

Authors:  Adam P Mecca; Hannah R Michalak; Julia W McDonald; Emily C Kemp; Erika A Pugh; Melinda L Becker; Marcia C Mecca; Christopher H van Dyck
Journal:  Dement Geriatr Cogn Disord       Date:  2018-06-08       Impact factor: 2.959

6.  Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.

Authors:  Paul Lochhead; Kaitlin Hagan; Amit D Joshi; Hamed Khalili; Long H Nguyen; Francine Grodstein; Andrew T Chan
Journal:  Gastroenterology       Date:  2017-07-18       Impact factor: 22.682

7.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

Review 8.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

9.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

10.  Serum Calcium Predicts Cognitive Decline and Clinical Progression of Alzheimer's Disease.

Authors:  Ling-Zhi Ma; Zi-Xuan Wang; Zuo-Teng Wang; Xiao-He Hou; Xue-Ning Shen; Ya-Nan Ou; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-11-20       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.